{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T07:59:58Z","timestamp":1781078398003,"version":"3.54.1"},"reference-count":22,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.clbc.2025.11.014","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T16:54:24Z","timestamp":1764608064000},"page":"131-138","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Survival Outcomes and Recurrence Patterns of Early-Stage HER2-Positive Breast Cancer Patients on Adjuvant T-DM1 Treatment: Turkish Oncology Group (TOG) Study"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5071-9679","authenticated-orcid":false,"given":"Alper","family":"T\u00fcrkel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9884-5789","authenticated-orcid":false,"given":"\u0130lknur Delikta\u015f","family":"Onur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4919-266X","authenticated-orcid":false,"given":"An\u0131l","family":"Karakayal\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6833-8217","authenticated-orcid":false,"given":"Merve B\u0131y\u0131kl\u0131","family":"Alemdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1540-3705","authenticated-orcid":false,"given":"Emine","family":"T\u00fcrkmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8253-5046","authenticated-orcid":false,"given":"Ali","family":"Alkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3817-8934","authenticated-orcid":false,"given":"Sedat","family":"Y\u0131ld\u0131z","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2575-5819","authenticated-orcid":false,"given":"Nargiz","family":"Majidova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1549-7326","authenticated-orcid":false,"given":"Gamze","family":"Emin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1455-471X","authenticated-orcid":false,"given":"Ali Fuat","family":"G\u00fcrb\u00fcz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1976-3951","authenticated-orcid":false,"given":"Elif","family":"\u015eahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2749-9414","authenticated-orcid":false,"given":"Teoman","family":"\u015eakalar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0260-7511","authenticated-orcid":false,"given":"\u00d6zge","family":"Yal\u0131c\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4859-7574","authenticated-orcid":false,"given":"Atike P\u0131nar","family":"Erdo\u011fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6363-2502","authenticated-orcid":false,"given":"Ramazan","family":"Co\u015far","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4264-8214","authenticated-orcid":false,"given":"Elanur","family":"Karaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2597-5931","authenticated-orcid":false,"given":"Melek Karakurt","family":"Ery\u0131lmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9359-3770","authenticated-orcid":false,"given":"Mutlu","family":"Do\u011fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clbc.2025.11.014_bib0001","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"10.1016\/j.clbc.2025.11.014_bib0002","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17071102","article-title":"Molecular subtypes and mechanisms of breast cancer: precision medicine approaches for targeted therapies","volume":"17","author":"Carvalho","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.clbc.2025.11.014_bib0003","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1158\/1055-9965.EPI-16-0520","article-title":"Cancer incidence and survival trends by subtype using data from the surveillance epidemiology and end results program, 1992-2013","volume":"26","author":"Noone","year":"2017","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"20","key":"10.1016\/j.clbc.2025.11.014_bib0004","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical practice guideline focused update","volume":"36","author":"Wolff","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2025.11.014_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102286","article-title":"Targeting HER2 heterogeneity in breast cancer","volume":"100","author":"Hamilton","year":"2021","journal-title":"Cancer Treat Rev"},{"issue":"34","key":"10.1016\/j.clbc.2025.11.014_bib0006","doi-asserted-by":"crossref","first-page":"5700","DOI":"10.1200\/JCO.2009.23.2025","article-title":"High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller","volume":"27","author":"Gonzalez-Angulo","year":"2009","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.clbc.2025.11.014_bib0007","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1200\/JCO.2013.52.0858","article-title":"Distant invasive breast cancer recurrence risk in human epidermal growth factor receptor 2-positive T1a and T1b node-negative localized breast cancer diagnosed from 2000 to 2006: a cohort from an integrated health care delivery system","volume":"32","author":"Fehrenbacher","year":"2014","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.clbc.2025.11.014_bib0008","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1200\/JCO.20.01204","article-title":"Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer in the APHINITY trial: 6 years' Follow-up","volume":"39","author":"Piccart","year":"2021","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clbc.2025.11.014_bib0009","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1056\/NEJMoa2406070","article-title":"Survival with trastuzumab emtansine in residual HER2-positive breast cancer","volume":"392","author":"Geyer","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2025.11.014_bib0010","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Breast Cancer. Version 4.2025. 2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf. Accessed September 7, 2025."},{"issue":"2","key":"10.1016\/j.clbc.2025.11.014_bib0011","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"35","author":"Loibl","year":"2024","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.clbc.2025.11.014_bib0012","doi-asserted-by":"crossref","DOI":"10.1093\/bjsopen\/zrac028","article-title":"Pathological complete response as a surrogate to improved survival in human epidermal growth factor receptor-2-positive breast cancer: systematic review and meta-analysis","volume":"6","author":"Davey","year":"2022","journal-title":"BJS Open"},{"key":"10.1016\/j.clbc.2025.11.014_bib0013","article-title":"Meta-analysis of HER2-enriched subtype predicting the pathological complete response within HER2-positive breast cancer in patients who received neoadjuvant treatment","volume":"11","author":"Shen","year":"2021","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.clbc.2025.11.014_bib0014","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s10549-015-3479-z","article-title":"Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials","volume":"152","author":"Loibl","year":"2015","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.clbc.2025.11.014_bib0015","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","article-title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial","volume":"13","author":"Gianni","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2025.11.014_bib0016","doi-asserted-by":"crossref","DOI":"10.1177\/11795549241260418","article-title":"Use of antibody-drug conjugates in the early setting of breast cancer","volume":"18","author":"Koukoutzeli","year":"2024","journal-title":"Clin Med Insights Oncol"},{"issue":"23","key":"10.1016\/j.clbc.2025.11.014_bib0017","doi-asserted-by":"crossref","first-page":"7381","DOI":"10.1158\/1078-0432.CCR-09-1735","article-title":"Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes","volume":"15","author":"Mittendorf","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.clbc.2025.11.014_bib0018","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41416-019-0635-y","article-title":"Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer","volume":"122","author":"Hunter","year":"2020","journal-title":"Br J Cancer"},{"issue":"7","key":"10.1016\/j.clbc.2025.11.014_bib0019","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/annonc\/mdy536","article-title":"PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab","volume":"30","author":"Loibl","year":"2019","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.clbc.2025.11.014_bib0020","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.clbc.2018.02.010","article-title":"Early stage HER2-positive breast cancers not achieving a pCR from neoadjuvant trastuzumab- or pertuzumab-based regimens have an immunosuppressive phenotype","volume":"18","author":"Force","year":"2018","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.clbc.2025.11.014_bib0021","doi-asserted-by":"crossref","unstructured":"Turcotte, M, D Allard, D Mittal, et al. CD73 Promotes resistance to HER2\/ErbB2 antibody therapy. Cancer Res, 2017. 77(20): 5652-63 DOI: 10.1158\/0008-5472.Can-17-0707.","DOI":"10.1158\/0008-5472.CAN-17-0707"},{"issue":"24_Supplement","key":"10.1016\/j.clbc.2025.11.014_bib0022","doi-asserted-by":"crossref","first-page":"S6-7","DOI":"10.1158\/0008-5472.SABCS12-S6-7","article-title":"Abstract S6-7: adaptive immune system and immune checkpoints are associated with response to pertuzumab (P) and trastuzumab (H) in the NeoSphere study","volume":"72","author":"Gianni","year":"2012","journal-title":"Cancer Res"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152682092500343X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152682092500343X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T07:26:10Z","timestamp":1781076370000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152682092500343X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S152682092500343X"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2025.11.014","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Survival Outcomes and Recurrence Patterns of Early-Stage HER2-Positive Breast Cancer Patients on Adjuvant T-DM1 Treatment: Turkish Oncology Group (TOG) Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2025.11.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}